The Asia Consensus Statement (ACS) on the NCCN Guideline (NCCN-ACS) for treatment of bladder cancer version 1.2016 is designed to provide documentation of modifications of the 'parent' NCCN Guideline: Bladder Cancer (Version 2.2015). When considering ethnic differences or differences in health regulatory environments between Western and Asian countries, a process of adaptation to match the circumstances is helpful for utilizing the guidelines. The NCCN-ACS for bladder cancer consist of 11 ACSs, focused on diagnosis, imaging, surgical treatment, adjuvant intravesical chemotherapy or immunotherapy, periopererative (neodjuvant or adjuvant) chemotherapy and radiation oncology including bladder preservation. This mini-review will briefly summarize the bladder cancer version 1.2016 of the NCCN-ACS.
Introduction
The National Comprehensive Cancer Network (NCCN) Guideline for bladder cancer is a well-known and widely used treatment guide, but NCCN guidelines are largely based on established evidence from Western countries. When considering ethnic differences and cultural diversity in Asian countries, along with differences in health regulatory environments, a process of adaptation to suit the circumstances is needed to effectively utilize the guidelines (1) . The Asia Consensus Statement (ACS) on the NCCN Guideline (NCCN-ACS) for bladder cancer version 1.2016 was published for this purpose (2) . The statement refers to the NCCN Guidelines: Bladder Cancer (Version 2.2015). Twenty-two panelists from 10 Asian countries, all of them multidisciplinary specialists, participated in production of the NCCN-ACS on bladder cancer. As shown in Table 1 , the NCCN-ACS for bladder cancer consists of 11 ACSs, focused on imaging and diagnosis, surgical treatment, adjuvant intravesical chemotherapy or immunotherapy, perioperative (neodjuvant or adjuvant) chemotherapy and radiation oncology including bladder preservation. The NCCN-ACS also contains informative appendices about the epidemiology and treatment of bladder cancer in Asian countries. This minireview will briefly summarize the bladder cancer version 1.2016 of the NCCN-ACS.
Bladder cancer incidence and mortality rates in Asian countries
An estimated 148 568 new cases of bladder cancer were diagnosed in Asian countries (115 646 men and 32 922 women) in 2012. Bladder cancer is the 14th most common cancer in Asia. During the same year, 69 294 deaths (52 816 men and 16 478 women) resulted from bladder cancer in Asian countries. Figure 1 shows the estimated incidences and mortality rates of bladder cancer in Asian countries based on GLOBOCAN 2012 v.1.0 (3) and other sources. The incidence and mortality in Asian countries ranged from 1.5 to 6.6 per 100 000 and from 0.7 to 2.6 per 100 000, respectively. The incidences in Asian countries were much lower than that of the United States (11.6 per 100 000) (3). Figure 2 shows the mortality/incidence ratios of bladder cancer in Asian countries. The ratios ranged from 0.21 to 0.56 among countries. The lowest country was Singapore (0.21), followed by Japan (0.25).
ACSs on diagnosis, imaging and pathological staging for bladder cancer
Office cystoscopy is the first step for the diagnosis of bladder cancer, but panel members concluded that preference for a rigid or a flexible cystoscope varies among countries (ACS#1). A rigid cystoscope is usually used in China, the Philippines and Taiwan, while either a rigid or a flexible cystoscopy is used in the other countries. According to data collected from panel members as of July 2015, panelists from Hong Kong and Singapore reported that only a flexible cystoscope is used, and the panelists from Japan asserted that a flexible cystoscope is more popular than a rigid cystoscope. The panel also concluded that the indications for a bone scan are different in some Asian countries than those in others (ACS#2). In the Philippines, symptomatic patients or those who present with elevated alkaline phosphatase (ALP) usually undergo a bone scan for muscle-invasive bladder cancer (MIBC). The indications for a bone scan are the same in most other Asian countries. In Japan, however, a bone scan is a common practice for MIBC, regardless of the ALP levels or symptoms. But, according to the clinical guideline for bladder cancer in Japan (2015 version), a bone scan is not routinely performed in initially diagnosed MIBC patients unless ALP levels is high or presence of bone pain.
Among radiological imaging methods for non-muscle-invasive bladder cancer (NMIBC), computed tomography (CT) is the first choice for the workup in many Asian countries. In South Korea, chest CT is not routinely performed but is considered if abnormal findings are detected on a plain chest X-ray. In Japan, CT and bone scintigraphy are used for N and M staging, and positron emission tomography (PET) is also an option. MRI is mainly used for clinical T staging in Japan. In South Korea, MRI is believed to be helpful in cases Mortality/incidence ratios of bladder cancer in Asian countries. The mortality/incidence ratios were calculated from the estimated incidence and mortality rates of bladder cancer.
suspicious of >T3 or invasion to pelvic bones. In the Philippines, MRI is used only for selected cases when better delineation of possible extra-vesical extension is desired. Both intravenous pyelogram (IVP) and intravenous urography (IVU) were used mostly for the detection of cancer in the renal pelvis and ureter. However, IVP and IVU are rarely used in many Asian countries except in facilities lacking other modalities such as CT and MRI. In fact, IVP and IVU could substitute for imaging during CT urography. Therefore, the panel concluded that imaging of the upper tract collecting system includes one or more of the following: CT urography, renal ultrasound, or CT with retrograde pyelogram, ureteroscopy, MRI urogram and IVP or IVU (ACS #4). The panel discussed the following points on pathological staging. In many Asian countries, there is no disagreement with the NCCN Guideline (Version 2.2015) that pathologic ('p') staging cannot be done without radical cystectomy. In Japan and South Korea, however, 'p' staging can be performed using an endoscopically sampled specimen (biopsy or TUR). In Taiwan, 'p' staging is done in some facilities if a muscle layer is included in an endoscopically sampled specimen. In the Philippines, deep muscle biopsy is mandatory in transurethral resection of bladder tumor (TURBT) to accurately determine the pathological staging of the primary tumor. The difference in the criteria for 'p' staging among some Asian countries may result from differences of the TNM staging between AJCC and UICC. The general rules of the TNM system of UICC (7th ed., 2009) state that 'pathological assessment of primary tumor (pT) entails a resection of the primary tumor or biopsy adequate to evaluate the highest pT category' (4). When a TURBT sample includes a muscle layer and the tumor is not embedded in the muscle layer, 'p' staging can be done. Therefore, the panel concluded on pathological staging as follows (ACS#11): the TNM staging system of AJCC (7th ed., 2010) in the NCCN guidelines is different from that of UICC (7th ed., 2009).
ACSs on surgical treatment
The panel discussed the following points on primary evaluation and surgical treatment for NMIBC. Bimanual examination is easy to do, but its clinical importance and usefulness are controversial in many Asian countries. This method was deleted from the latest clinical guidelines in Japan and South Korea. However, bimanual examination during cystoscopy is mandatory in the Philippines. In the Philippines, mapping biopsies are recommended for patients with grossly suspicious mucosa. In China and Japan, random (preselected) biopsies at TURBT are recommended for risk stratification when concomitant carcinoma in situ (CIS) is suspected. If tumors in the trigone or bladder neck or multiple tumors are present, a biopsy of the prostatic urethra is also recommended (5, 6) . In South Korea, it is considered important to consider damage to the urothelium and the risk of tumor implantation, so selected mapping biopsies are indicated for patients scheduled for partial cystectomy or with unidentifiable/superficial-only tumor despite positive cytology. In Singapore, mapping biopsies are performed to pick up CIS, and the prostate biopsy used is to facilitate planning for cystectomy. In Indonesia, mapping biopsies should be performed on patients with positive cytology without visible tumor during cystoscopy. In Thailand, mapping biopsies are performed on patients with suspicion of CIS. According to the discussion, the panel concluded that TURBT is recommended as primary evaluation and treatment for NMIBC. If sessile, suspicious for high-grade tumor or Tis are found, mapping biopsy for selected patients should be performed and TUR biopsy of the prostate considered (ACS #3).
Generally, routine repeat transurethral resection is advised for NMBIC patients (7) . In Indonesia, radical cystectomy for high-grade cT1 is recommended when the patient has multiple >3 cm tumors. In South Korea, radical cystectomy is performed as a salvage treatment after the failure of bladder preservation or BCG therapy or when any unresectable tumor exists. In Japan, cystectomy is recommended in patients for whom BCG has failed, those with micropapillary or large high-grade T1 tumors, and those with residual T1 tumor in the second TUR specimens. In Taiwan and Thailand, cystectomy is considered only for high-grade T1. Repeat TUR is called second TUR in Asian countries. In Philippines, partial cystectomy is also recommended if feasible. According to the discussion, the panel strongly advises repeat TUR to decide the treatment strategy for cT1 tumor after primary evaluation (ACS #5), and also recommended cystectomy for highgrade tumor with additional conditions in some Asian countries.
ACSs on adjuvant intravesical chemotherapy or immunotherapy, perioprerative (neoadjuvant or adjuvant) chemotherapy
The panel concluded that chemotherapy is appropriate for adjuvant intravesical treatment after TURBT if BCG is not available as adjuvant treatment for high-grade NMIBC (ACS#6). The panel also discussed different conditions among countries on this point as follows. The Tice strain of BCG is used in South Korea and Taiwan. Both Tokyo 172 and Connaught strains have been used in Japan (8,9), but Connaught strains are not available due to cessation of production by the company in 2017. BCG is not available in some Asian countries, such as Indonesia. In these countries, chemotherapy is used as an adjuvant intravesical treatment after TURBT. The preference for doxorubicin or mitomycin C varies by country. Gemcitabine is used for patients who failed BCG, doxorubicin and mitomycin C treatment in some countries. In Japan and South Korea, the recommended regimen of intravesical BCG for CIS is once weekly for 6-8 weeks as induction therapy (10), every 3 months for 1 year, and every 6 months for the next 2 years as maintenance therapy.
For follow-up after adjuvant intravesical treatment, the panel concluded that most Asian centers perform cystoscopy at 3 months after adjuvant intravesical treatment, then at increasing intervals as appropriate (ACS#7). In the Philippines, cystoscopy is performed every 3 months for at least 1 year. In Taiwan, cystoscopy is conducted every 3 months for 1 year and then at increasing intervals as appropriate. In China and Japan, cystoscopy is carried out every 3 months for 2 years and then at increasing intervals as appropriate. Urinary urothelial markers such as nuclear matrix protein 22 (NMP22) and bladder tumor antigen (BTA) may be used in Asian countries. In Japan, NMP22 is approved as a screening test by the national health insurance system only for patients with a strong suspicion of urothelial carcinoma, while BTA is used for the detection of recurrent bladder cancer. In China, NMP22 is used but not mentioned in the clinical guidelines and is uncommon in Indonesia. In South Korea, cytology and NMP22 are common practices and covered by health insurance, although routine urine cytology can be cost-ineffective for the follow-up of NMIBC (11) . In the Philippines, NMP22 and BTA are both unavailable.
As perioperative chemotherapy, the panel described the following three regimens. MVAC (methotrexate, vinblastine, doxorubicin and cisplatin) with or without growth factor support for three or four cycles, gemcitabine and cisplatin for two to four cycles, and CMV (cisplatin, methotrexate and vinblastine) for three cycles (ACS#9). Both MVAC and GC are available in all Asian countries. In some Asian countries, GC is the first-line chemotherapy. Growth factor support during treatment with MVAC depends on the patient's condition. In China, adjuvant GC is commonly used with growth factor for four to six cycles. Also, in Japan, GC is preferred, and MVAC performed for two or three cycles, if used. Some panel members mentioned that dosedense MVAC (DDMVAC) has a high risk of side effects. Another panel member, however, preferred that we continue to consider DDMVAC as an option for perioperative chemotherapy.
ACSs on radiation oncology including bladder preservation
The panel discussed bladder preservation for cT2. In South Korea, radiation for bladder preservation is an option for patients for whom radical cystectomy is unsuitable. In the Philippines, many cT2 patients undergo radical cystectomy due to the high cost of neoadjuvant chemotherapy plus radiation. In China, standard TURBT + radiation + adjuvant chemotherapy is more common for bladder preservation than neoadjuvant chemotherapy. In Japan, some novel bladder preservation therapies have been examined (12) (13) (14) . In Taiwan, a full course of radiotherapy with 60-65 Gy is followed by cystoscopic re-evaluation of response 2-3 months later (15) . If residual tumor is documented, cystectomy is recommended. If no residual disease is identified and cytology/biopsy are negative, completion of full-course radiotherapy up to 66 Gy is recommended. Therefore, the panel concluded that perioperative treatments for bladder preservation vary considerably among Asian countries (ACS#8).
The NCCN guidelines (Version 2.2015) described simulate and treat when they have an empty bladder as principles of radiation management for MIBC. The panel concluded that 'simulate and treat when patients have an empty bladder' is acceptable in many Asian countries (ACS#10). However, the panel also reported that in some Asian countries, simulation and treatment are performed on either an empty or full bladder, based on simulation specifications.
Conclusion
The ASR of incidence of and mortality from bladder cancer varies in Asian countries. In addition, management of bladder cancer differs among countries.
